The following is a summary of "Improved Peyronie's Disease Curvature Outcomes Using a Novel Collagenase Administration Protocol," published in the December 2022 issue of Urology by Flores, et al. For a study, researchers sought to describe the results of a new collagenase injection procedure using Clostridium histolyticum (CCH). Since 2015, a prospective, sequential database of
Futura Medical plc (AIM: FUM), a pharmaceutical company developing a portfolio of innovative products based on its proprietary, transdermal DermaSys drug delivery technology and currently focused on